Poster
81
(#81) Real-World Impact of Olanzapine and Samidorphan on Rates of Relapse Among Young Adults With Schizophrenia or Bipolar I Disorder
Psych Congress 2025
Abstract: INTRODUCTION: Combined olanzapine/samidorphan (OLZ/SAM) is approved for the treatment of schizophrenia and bipolar I disorder (BD-I). In real-world studies, OLZ/SAM treatment significantly reduced acute care events (proxies for relapse) in the 12 months after initiating OLZ/SAM. This analysis examined relapse rates (disease-related acute care events) in a subgroup of young adults, a population vulnerable to relapse.
METHODS: This claims analysis used data from Komodo Healthcare Map (10/18/2020-12/31/2023). Adults aged 18-34 years with schizophrenia or BD-I, ≥1 OLZ/SAM claim, and ≥12 months' enrollment in medical/pharmacy benefits before and after the index date were eligible. Disease-related inpatient (IP) admissions and emergency department (ED) visits in 12-month baseline and follow-up periods were compared; results are presented as absolute percent changes. All-cause and mental health-related events were evaluated separately.
RESULTS: Overall, 564 patients with schizophrenia and 418 with BD-I were included. For patients with schizophrenia initiating OLZ/SAM, proportions of patients with ≥1 schizophrenia-related IP admission or ED visit decreased significantly by 12.1% and 6.2% between baseline and follow-up, respectively (both P 0.05). For patients with BD-I initiating OLZ/SAM, proportions of patients with ≥1 BD-I-related IP admission or ED visit decreased significantly by 18.7% and 6.7% between baseline and follow-up, respectively (both P 0.05). In both cohorts, reductions in disease-related acute care events were numerically larger than those reported previously for the main study.
CONCLUSIONS: For young adults with schizophrenia or BD-I who are in an earlier stage of their illness, initiating OLZ/SAM may be an effective strategy for reducing relapse.
Short Description: This subgroup analysis of a real-world claims study evaluated relapse rates in young adults (aged 18-34 years) with schizophrenia or bipolar I disorder initiating treatment with combined olanzapine/samidorphan (OLZ/SAM). OLZ/SAM treatment was associated with significantly reduced disease-related inpatient admissions and emergency department visits over 12 months of follow-up versus baseline. These data suggest that OLZ/SAM may be an effective treatment option for reducing relapse rates in early-stage illness.
Name of Sponsoring Organization(s): This study was sponsored by Alkermes, Inc. Medical writing and editorial support were provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Alkermes, Inc.
METHODS: This claims analysis used data from Komodo Healthcare Map (10/18/2020-12/31/2023). Adults aged 18-34 years with schizophrenia or BD-I, ≥1 OLZ/SAM claim, and ≥12 months' enrollment in medical/pharmacy benefits before and after the index date were eligible. Disease-related inpatient (IP) admissions and emergency department (ED) visits in 12-month baseline and follow-up periods were compared; results are presented as absolute percent changes. All-cause and mental health-related events were evaluated separately.
RESULTS: Overall, 564 patients with schizophrenia and 418 with BD-I were included. For patients with schizophrenia initiating OLZ/SAM, proportions of patients with ≥1 schizophrenia-related IP admission or ED visit decreased significantly by 12.1% and 6.2% between baseline and follow-up, respectively (both P 0.05). For patients with BD-I initiating OLZ/SAM, proportions of patients with ≥1 BD-I-related IP admission or ED visit decreased significantly by 18.7% and 6.7% between baseline and follow-up, respectively (both P 0.05). In both cohorts, reductions in disease-related acute care events were numerically larger than those reported previously for the main study.
CONCLUSIONS: For young adults with schizophrenia or BD-I who are in an earlier stage of their illness, initiating OLZ/SAM may be an effective strategy for reducing relapse.
Short Description: This subgroup analysis of a real-world claims study evaluated relapse rates in young adults (aged 18-34 years) with schizophrenia or bipolar I disorder initiating treatment with combined olanzapine/samidorphan (OLZ/SAM). OLZ/SAM treatment was associated with significantly reduced disease-related inpatient admissions and emergency department visits over 12 months of follow-up versus baseline. These data suggest that OLZ/SAM may be an effective treatment option for reducing relapse rates in early-stage illness.
Name of Sponsoring Organization(s): This study was sponsored by Alkermes, Inc. Medical writing and editorial support were provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Alkermes, Inc.
